Research programme: kinase inhibitors - Daiichi Sankyo/Teva Pharmaceutical Industries

Drug Profile

Research programme: kinase inhibitors - Daiichi Sankyo/Teva Pharmaceutical Industries

Alternative Names: CEP-17940; CEP-18050; CEP-28122; CEP-31933; CEP-40783; CEP-4416; CEP-7055; CEP-A; RXDX-106

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambit Biosciences Corporation; Cephalon
  • Developer Daiichi Sankyo Company; Ignyta; Teva Pharmaceutical Industries
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Axl receptor tyrosine kinase inhibitors; Proto oncogene protein b raf inhibitors; Proto oncogene protein c met inhibitors; Proto-oncogene protein c-mer inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 10 Nov 2017 Preclinical development is ongoing in USA
  • 08 Nov 2017 Ignyta plans clinical trials of RXDX 106 for Cancer in early 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top